MEK1 P124L mutation was observed in a metastatic tumor biopsy from a drug resistant melanoma patient upon MEKi AZD6244 treatment, while dual inhibition of MEK and BRAF can overcome the acquired resistance 73. This evidence concerns the gene MAP2K1 and melanoma.